CV Sciences FY2024 revenue $15.7M (-1.9% YoY), operating loss $2.2M vs income $3.4M in 2023

CV Sciences, Inc.

Revenue $15.7M vs $16.0M in 2023; Q4 revenue $3.9M (+2.2% YoY).
Gross margin improved to 45.6% from 44.3%; adjusted EBITDA loss narrowed to $0.8M from $2.3M.
Cash balance $0.5M at year-end vs $1.3M; net proceeds of $0.9M from Streeterville financing in Q3 2024.
Acquired Elevated Softgels in Q2 2024; launched +PlusHLTH brand and Lunar Fox plant-based line.
Retained Maxim Group as non-exclusive financial advisor; evaluating M&A opportunities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.